Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.

The phenolic group of the potent mu and kappa opioid morphinan agonist/antagonists cyclorphan and butorphan was replaced by phenylamino and benzylamino groups including compounds with para-substituents in the benzene ring. These compounds are highly potent mu and kappa ligands, e.g., p-methoxyphenylaminocyclorphan showing a K(i) of 0.026 nM at the mu receptor and a K(i) of 0.03 nM at the kappa receptor. Phenyl carbamates and phenylureas were synthesized and investigated. Selective o-formylation of butorphan and levorphanol was achieved. This reaction opened the way to a large set of 2-substituted 3-hydroxymorphinans, including 2-hydroxymethyl-, 2-aminomethyl-, and N-substituted 2-aminomethyl-3-hydroxymorphinans. Bivalent ligands bridged in the 2-position were also synthesized and connected with secondary and tertiary aminomethyl groups, amide bonds, and hydroxymethylene groups, respectively. Although most of the 2-substituted morphinans showed considerably lower affinities compared to their parent compounds, the bivalent ligand approach led to significantly higher affinities compared to the univalent 2-substituted morphinans.

[1]  J. Neumeyer,et al.  In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. , 2007, Bioorganic & medicinal chemistry.

[2]  J. Neumeyer,et al.  High-affinity carbamate analogues of morphinan at opioid receptors. , 2007, Bioorganic & medicinal chemistry letters.

[3]  J. Neumeyer,et al.  Kappa receptor bivalent ligands. , 2007, Current topics in medicinal chemistry.

[4]  Amy L. Parkhill,et al.  Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine. , 2006, Journal of medicinal chemistry.

[5]  T. Hansen,et al.  ortho‐Formylation of Phenols; Preparation of 3‐Bromosalicylaldehyde , 2005 .

[6]  Irina D Pogozheva,et al.  Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. , 2004, Biochemistry.

[7]  A. Zhang,et al.  2-aminothiazole-derived opioids. Bioisosteric replacement of phenols. , 2004, Journal of medicinal chemistry.

[8]  A. Zhang,et al.  10-Ketomorphinan and 3-Substituted-3-desoxymorphinan Analogues as Mixed κ and μ Opioid Ligands: Synthesis and Biological Evaluation of Their Binding Affinity at Opioid Receptors , 2004 .

[9]  N. Mello,et al.  Design and Synthesis of Novel Dimeric Morphinan Ligands for κ and μ Opioid Receptors , 2003 .

[10]  J. Neumeyer,et al.  Synthesis of aminothiazole derived morphinans , 2003 .

[11]  J. Neumeyer,et al.  Microwave-promoted Pd-catalyzed cyanation of aryl triflates: a fast and versatile access to 3-cyano-3-desoxy-10-ketomorphinans. , 2003, Organic letters.

[12]  T. Shippenberg,et al.  Effects of the Kappa-opioid Receptor Agonist, U69593, on the Development of Sensitization and on the Maintenance of Cocaine Self-administration , 2001, Neuropsychopharmacology.

[13]  B. Hope,et al.  Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine , 2000, Neuroscience.

[14]  J. Bidlack,et al.  Selective protection and functionalization of morphine: synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives. , 2000, Journal of Medicinal Chemistry.

[15]  N. Mello,et al.  Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. , 2000, Pharmaceutica acta Helvetiae.

[16]  J. Bidlack,et al.  8-Aminocyclazocine analogues: synthesis and structure-activity relationships. , 2000, Bioorganic & medicinal chemistry letters.

[17]  N. Mello,et al.  Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. , 2000, Journal of medicinal chemistry.

[18]  H. Kubota,et al.  Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives. , 1998, Bioorganic & medicinal chemistry letters.

[19]  S. Buchwald,et al.  An Ammonia Equivalent for the Palladium-Catalyzed Amination of Aryl Halides and Triflates , 1997 .

[20]  S. Buchwald,et al.  Palladium-Catalyzed Amination of Aryl Triflates , 1997 .

[21]  J. Hartwig,et al.  Palladium-Catalyzed Amination of Aryl Triflates and Importance of Triflate Addition Rate , 1997 .

[22]  L. Terenius,et al.  PALLADIUM-CATALYZED SYNTHESIS OF C3-SUBSTITUTED 3-DEOXYMORPHINES , 1994 .

[23]  J. P. Long,et al.  Enantiomers of 11-hydroxy-10-methylaporphine having opposing pharmacological effects at 5-HT1A receptors. , 1991, Chirality.

[24]  L. Porterfield Narcotic analgesics--I. , 1970, Advancing clinical care : official journal of NOAADN.

[25]  B. Tóth,et al.  The capsaicinoids: Their separation, synthesis, and mutagenicity , 1988 .

[26]  A. Brossi,et al.  DEOXYMORPHINES: ROLE OF THE PHENOLIC HYDROXYL IN ANTINOCICEPTION AND OPIATE RECEPTOR INTERACTIONS , 1979 .

[27]  L. Harris,et al.  Narcotic and narcotic antagonist analgesics. , 1967, Annual review of pharmacology.